Rohin Mhatre - 26 May 2022 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Kimberly Brown (Attorney in Fact)
Issuer symbol
RGEN
Transactions as of
26 May 2022
Net transactions value
$0
Form type
4
Filing time
31 May 2022, 20:25:11 UTC
Previous filing
17 May 2021
Next filing
22 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +1,202 +263% $0.000000 1,659 26 May 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +2,920 $0.000000 2,920 26 May 2022 Common Stock 2,920 $159.17 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Mhatre was awarded 1,202 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 26, 2023, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Award vests in full on the earlier of May 26, 2023, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.